<SUBMISSION>
<ACCESSION-NUMBER>0000950123-10-072318
<TYPE>425
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20100804
<DATE-OF-FILING-DATE-CHANGE>20100804
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>425
<ACT>34
<FILE-NUMBER>001-33657
<FILM-NUMBER>10990234
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>CELGENE CORP /DE/
<CIK>0000816284
<ASSIGNED-SIC>2834
<IRS-NUMBER>222711928
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>425
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
<PHONE>(908)673-9000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>c04365e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): August 4, 2010</B>

<P style="font-size: 24pt" align="center"><B>CELGENE CORPORATION<BR>
</B><FONT
style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-16132</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>22-2711928</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>86 Morris Avenue, Summit, New
Jersey<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07901</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 673-9000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">&#254;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ITEM 8.01 OTHER EVENTS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;4, 2010, Celgene Corporation (Celgene) announced that it has received verbal confirmation
of early termination of the Hart-Scott-Rodino Act (HSR)&nbsp;30-day waiting period without the United
States Federal Trade Commission (FTC)&nbsp;requesting additional information with regard to Celgene&#146;s
pending acquisition of Abraxis Bioscience, Inc. A copy of the press release is filed herewith as
Exhibit&nbsp;99.1 and is incorporated herein by reference.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Celgene anticipates that the transaction will be completed in the third or fourth quarter of 2010.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Exhibit&nbsp;99.1 &#151; Press Release dated August&nbsp;4, 2010
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This exhibit is furnished pursuant to Item&nbsp;8.01 and shall not be deemed to be &#147;filed.&#148;
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CELGENE CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  August 4, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David W. Gryska
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David W. Gryska&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President and<BR>
Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c04365exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Exhibit&nbsp;99.1
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">David W. Gryska
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tim Smith</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Senior Vice President and
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Relations</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Celgene Corporation
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Celgene Corporation</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(908) 673-9059
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(908) 673-9951</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CELGENE/ABRAXIS RECEIVE VERBAL CONFIRMATION OF EARLY TERMINATION OF HART-SCOTT-RODINO (HSR)&nbsp;30-DAY WAITING PERIOD</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>SUMMIT, NJ &#151; (August&nbsp;4, 2010) </B>&#151; Celgene Corporation (NASDAQ: CELG) today announced that it has
received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR)&nbsp;30-day waiting
period without the United States Federal Trade Commission (FTC)&nbsp;requesting additional information
with regard to Celgene&#146;s pending acquisition of Abraxis Bioscience, Inc. (NASDAQ: ABII).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Celgene anticipates that the transaction will be completed in the third or fourth quarter of 2010.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Celgene</B><BR>
Celgene Corporation, headquartered in Summit, New Jersey is an integrated global pharmaceutical
company engaged primarily in the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the Company&#146;s website at www.celgene.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Abraxis BioScience, Inc.</B><BR>
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery,
development and delivery of next-generation therapeutics and core technologies that offer patients
safer and more effective treatments for cancer and other critical illnesses. The company&#146;s
portfolio includes chemotherapeutic compound (ABRAXANE), which is based on the company&#146;s
proprietary tumor targeting technology known as the <I>nab</I><SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> platform. The first FDA
approved product to use this <I>nab </I>platform, ABRAXANE, was launched in 2005 for the treatment of
metastatic breast cancer and is now approved in 39 countries. The company continues to expand the
<I>nab </I>platform through a robust clinical program and deep product pipeline. Abraxis trades on the
NASDAQ Global Market under the symbol ABII. For more information about the company and its
products, please visit http://www.abraxisbio.com.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>This release contains certain forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the company&#146;s control. The company&#146;s actual
results, performance, or achievements could be materially different from those projected by these
forward-looking statements. The factors that could cause actual results, performance, or
achievements to differ from the forward-looking statements are discussed in the company&#146;s filings
with the Securities and Exchange Commission, such as the company&#146;s </I><I>Form 10-K</I><I>, 10-Q and 8-K reports.
Given these risks and uncertainties, you are cautioned not to place undue reliance on the
forward-looking statements.</I>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
